Terms: = Breast cancer AND SLC34A2, ENSG00000157765, O95436, NPTIIb, NAPI-IIb, NAPI-3B, FLJ90534, 10568
11 results:
1. Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability.
Hong S; Xie Y; Cheng Z; Li J; He W; Guo Z; Zhang Q; Peng S; He M; Yu S; Xu L; Liu R; Xu T; Zhang Y; Li Y; Wang J; Lv W; Yu J; Xiao H
Oncogene; 2022 Nov; 41(47):5121-5132. PubMed ID: 36253446
[TBL] [Abstract] [Full Text] [Related]
2. Characterization of
Vlasenkova R; Nurgalieva A; Akberova N; Bogdanov M; Kiyamova R
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944522
[TBL] [Abstract] [Full Text] [Related]
3. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer.
Felicio PS; Grasel RS; Campacci N; de Paula AE; Galvão HCR; Torrezan GT; Sabato CS; Fernandes GC; Souza CP; Michelli RD; Andrade CE; Barros BDF; Matsushita MM; Revil T; Ragoussis J; Couch FJ; Hart SN; Reis RM; Melendez ME; Tonin PN; Carraro DM; Palmero EI
Hum Mutat; 2021 Mar; 42(3):290-299. PubMed ID: 33326660
[TBL] [Abstract] [Full Text] [Related]
4. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract] [Full Text] [Related]
5. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract] [Full Text] [Related]
6. Solute carrier family 34 member 2 overexpression contributes to tumor growth and poor patient survival in colorectal cancer.
Liu L; Yang Y; Zhou X; Yan X; Wu Z
Biomed Pharmacother; 2018 Mar; 99():645-654. PubMed ID: 29653487
[TBL] [Abstract] [Full Text] [Related]
7. Characterization of inorganic phosphate transport in the triple-negative breast cancer cell line, MDA-MB-231.
Russo-Abrahão T; Lacerda-Abreu MA; Gomes T; Cosentino-Gomes D; Carvalho-de-Araújo AD; Rodrigues MF; Oliveira ACL; Rumjanek FD; Monteiro RQ; Meyer-Fernandes JR
PLoS One; 2018; 13(2):e0191270. PubMed ID: 29415049
[TBL] [Abstract] [Full Text] [Related]
8. The effects and mechanisms of slc34a2 on maintaining stem cell-like phenotypes in CD147
Lv Y; Wang T; Fan J; Zhang Z; Zhang J; Xu C; Li Y; Zhao G; He C; Meng H; Yang H; Wang Z; Liu J; Chen J; Wang L
Tumour Biol; 2017 Apr; 39(4):1010428317695927. PubMed ID: 28381172
[TBL] [Abstract] [Full Text] [Related]
9. Enhanced slc34a2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via slc34a2-Bmi1-ABCC5 signaling.
Ge G; Zhou C; Ren Y; Tang X; Wang K; Zhang W; Niu L; Zhou Y; Yan Y; He J
Tumour Biol; 2016 Apr; 37(4):5049-62. PubMed ID: 26546432
[TBL] [Abstract] [Full Text] [Related]
10. Identification of ROS1 rearrangement in gastric adenocarcinoma.
Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
[TBL] [Abstract] [Full Text] [Related]
11. slc34a2 as a novel marker for diagnosis and targeted therapy of breast cancer.
Chen DR; Chien SY; Kuo SJ; Teng YH; Tsai HT; Kuo JH; Chung JG
Anticancer Res; 2010 Oct; 30(10):4135-40. PubMed ID: 21036732
[TBL] [Abstract] [Full Text] [Related]
